G. Cierny, MD: Tobacco abuse and Hyperbaric Oxygen treatments when treating osteomyelitis (”bone infection”) and/or peri-prosthetic total joint infections. Thank you for your questions. I worked with Jon T Mader, MD in Galveston, TX 1980-1985 and also ran the HBO Treatment Centers at Crawford Long and St. Josephs Hospitals, in Atlanta, 1986 – 2003. In cases where I completely removed all the tissues compromised by disease /infection at the time of the debridement surgery, we saw no benefit to outcomes in a randomized trial of patients (both A-hosts and B-hosts) treated for osteomyelitis, 1981-1988 (No=188). It was only when residual disease (or ischemia) was retained that pre- and post-operative HBO had its place in reducing both failures and complications (ie; radiation necrosis, peripheral vascular disease, etc). This study was presented and recorded at Dick Clarke’s HBO course, South Carolina (Cierny.Mader; 1989) .
So far as tobacco use: I have come the conclusion that patient education is the best approach to take with patients who require treatment for infection. I let them know the down side of continued tobacco use during treatment and tell both the patient and their support(family) that continued use may lead to consequences that they, alone, will have to bare: added expense, disability, surgery, and the possible need for ablation, for failure. They (b-hosts) are quoted a 20-30% increase in failure and complication rates.
When looking at bone transport and regenerate formation using the methods of Professor Gabriel Ilizarov, we found smokers had a 30% increase in disability time and time-to-union compared to non-smokers. We also observed that all of the patients suffering a regenerate failure (new bone growth) were smokers. Those patients who did manage to quit smoking throughout treatment had results equal to non-smokers (Smokers Suffer Impaired Bone Healing. SCIENCE NEWS, Vol. 141, February 29, 1992). Similarly, if you look at our outcomes when treating peri-prosthetic total joint infections (total hip, total knee, total shoulder), at two years, B-hosts with < 3 major co-morbidities had a 90-93% success rate compared to 97% success for A-hosts and 66% success for those patients with > 3 co-morbidities. However, 17% of those with <3 co-morbidities underwent a 3-stage or a second 2-stage protocol to achieve a successful outcome.
When faced with a truly elective surgery, I try not to ever operate a patient with a reversible compromise to healing before that compromise is either eliminated or optimized (smoking, mal-nutrition, radiation necrosis, diabetes, etc). However, when faced with an infection, treatment is often not elective. Historically speaking (our experience 1983 -2007: 2207 patients), less than 40% of those who say they will quit at the time of presentation never do, when chemiclly screen-tested throughout treatment. So, my policy with these patients is as follows: “Here are the choices; here is the science; here are the anticipated outcomes if you do not refrain from tobacco use during treatment. Let me know how you want to proceed.” GCIII 10/16/09